Lilly nasal insulin
Executive Summary
Lilly has decided to continue funding development of California Biotechnology's Nazdel nasal drug delivery technology for use with insulin, Cal Bio announced Sept. 26. The biotech firm will receive payments that "could amount to more than $10 mil. during the next five to six years, contingent on achievement of various product development milestones" plus royalties, Cal Bio said.